No label defined (Q3166008)

From EU Knowledge Graph
Revision as of 16:30, 12 October 2021 by DG Regio (talk | contribs) (‎Created claim: summary (P836): B-cell non-Hodgkin lymphomas (NHL) constitute a very heterogeneous group of malignant lymphoproliferative diseases, both biologically and clinically, consisting of more than 40 neoplasms ranging from indolent to highly aggressive diseases. Although survival after chemotherapeutic treatment has increased in recent years, some patients with B-cell NHL are relapsed due to drug resistance, presenting unfavorable prognosis, so the identification of n...)
Jump to navigation Jump to search
Project Q3166008 in Spain
Language Label Description Also known as
English
No label defined
Project Q3166008 in Spain

    Statements

    contained in NUTS
    Biscay
    0 references
    country
    Spain
    0 references
    EU contribution
    33,250.0 Euro
    0 references
    budget
    66,500.0 Euro
    0 references
    co-financing rate
    50.0 percent
    0 references
    start time
    1 January 2019
    0 references
    end time
    31 March 2022
    0 references
    beneficiary name (string)
    ASOCIACION INSTITUTO DE INVESTIGACION SANITARIA BIOCRUCES
    0 references
    beneficiary
    Q3134851
    0 references
    coordinate location

    43°17'43.73"N, 2°59'24.32"W
    0 references
    postal code
    48013
    0 references
    summary
    Los linfomas no-Hodgkin (LNH) de células B constituyen un grupo de enfermedades malignas linfoproliferativas muy heterogéneo, tanto a nivel biológico como clínico, constituido por más de 40 neoplasias que abarcan desde enfermedades indolentes hasta altamente agresivas. Aunque la supervivencia tras tratamiento quimioterapéutico ha aumentado en los últimos años, algunos pacientes con LNH de células B sufren recaídas debido a la resistencia a fármacos, presentando pronóstico desfavorable, por lo que urge la identificación de nuevos marcadores pronósticos y dianas terapéuticas. La podocalicina (PCLP1), una molécula implicada en la adhesión e invasión tumorales, se expresa anormalmente en varios tipos de tumores y se asocia con los tipos de cáncer más agresivos. PCLP1 contribuye a la proliferación y supervivencia de las células Raji de linfoma de Burkitt, un tipo de LNH células B. El objetivo del presente proyecto es estudiar la implicación de PCLP1 en el desarrollo de diferentes tipos de LNH de células B y los mecanismos subyacentes. Para ello, se determinará la expresión de PCLP1 en muestras de pacientes que presentan estas neoplasias mediante citometría de flujo, así como su correlación con las características clínico-patológicas de los pacientes. Además, se analizará el efecto de la expresión de PCLP1 en la proliferación y viabilidad celulares y en la resistencia a agentes quimioterapéuticos. Finalmente, se evaluará el papel de PCLP1 en reprogramación metabólica de LNH de células B mediante la determinación de metabolitos y enzimas inducidos por la expresión de esta proteína por espectrometría de masas e inmunotranferencia y mediante el uso de inhibidores específicos de rutas metabólicas. Este estudio permitirá valorar la utilidad de PCLP1 como marcador diagnóstico y pronóstico y como posible diana terapéutica en estas enfermedades. (Spanish)
    0 references
    B-cell non-Hodgkin lymphomas (NHL) constitute a very heterogeneous group of malignant lymphoproliferative diseases, both biologically and clinically, consisting of more than 40 neoplasms ranging from indolent to highly aggressive diseases. Although survival after chemotherapeutic treatment has increased in recent years, some patients with B-cell NHL are relapsed due to drug resistance, presenting unfavorable prognosis, so the identification of new prognostic markers and therapeutic targets is urgent. Podocalicin (PCLP1), a molecule involved in tumor adhesion and invasion, is abnormally expressed in various types of tumors and is associated with the most aggressive types of cancer. PCLP1 contributes to the proliferation and survival of Raji cells of Burkitt lymphoma, a type of NHL B cells. The objective of this project is to study the involvement of PCLP1 in the development of different types of B-cell NHL and the underlying mechanisms. To do this, the expression of PCLP1 will be determined in samples of patients presenting these neoplasms by flow cytometry, as well as their correlation with the clinical and pathological characteristics of the patients. In addition, the effect of PCLP1 expression on cell proliferation and viability and resistance to chemotherapeutic agents will be analysed. Finally, the role of PCLP1 in metabolic reprogramming of B-cell NHL will be evaluated by determining metabolites and enzymes induced by the expression of this protein by mass spectrometry and immunotranference and by using specific metabolic route inhibitors. This study will assess the usefulness of PCLP1 as a diagnostic and prognostic marker and as a possible therapeutic target in these diseases. (English)
    point in time
    12 October 2021
    0 references
    location (string)
    Barakaldo
    0 references

    Identifiers

    Spanish Kohesio ID
    PI18_00629
    0 references
     
    Retrieved from "https://linkedopendata.eu/w/index.php?title=Item:Q3166008&oldid=12821339"